TY  - JOUR

T1  - DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

JO  - Journal of Clinical Oncology

UR  - http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5103

PY  - 2022/06/01

AU  - Niazi T

AU  - McBride SM

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Bracken K

AU  - Roncolato F

AU  - Horvath L

AU  - Sengupta S

AU  - Martin J et al

ED  - 

DO  - DOI: 10.1200/jco.2022.40.16_suppl.tps5103

PB  - American Society of Clinical Oncology (ASCO)

VL  - 40

IS  - 16_suppl

SP  - TPS5103

EP  - TPS5103

Y2  - 2024/12/29

ER  -